Cargando…

Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans

CONTEXT: Serum soluble leptin receptor (sOb-R) may protect against future type 2 diabetes or serve as a marker for protective features, but how sOb-R is regulated is largely unknown. OBJECTIVE: This work aimed to test how serum sOb-R is influenced by glucose, insulin, body fat, body mass index (BMI)...

Descripción completa

Detalles Bibliográficos
Autores principales: Sommer, Christine, Vangberg, Kjersti G, Moen, Gunn-Helen, Evans, David M, Lee-Ødegård, Sindre, Blom-Høgestøl, Ingvild K, Sletner, Line, Jenum, Anne K, Drevon, Christian A, Gulseth, Hanne L, Birkeland, Kåre I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099165/
https://www.ncbi.nlm.nih.gov/pubmed/36459457
http://dx.doi.org/10.1210/clinem/dgac699
_version_ 1785024992771047424
author Sommer, Christine
Vangberg, Kjersti G
Moen, Gunn-Helen
Evans, David M
Lee-Ødegård, Sindre
Blom-Høgestøl, Ingvild K
Sletner, Line
Jenum, Anne K
Drevon, Christian A
Gulseth, Hanne L
Birkeland, Kåre I
author_facet Sommer, Christine
Vangberg, Kjersti G
Moen, Gunn-Helen
Evans, David M
Lee-Ødegård, Sindre
Blom-Høgestøl, Ingvild K
Sletner, Line
Jenum, Anne K
Drevon, Christian A
Gulseth, Hanne L
Birkeland, Kåre I
author_sort Sommer, Christine
collection PubMed
description CONTEXT: Serum soluble leptin receptor (sOb-R) may protect against future type 2 diabetes or serve as a marker for protective features, but how sOb-R is regulated is largely unknown. OBJECTIVE: This work aimed to test how serum sOb-R is influenced by glucose, insulin, body fat, body mass index (BMI), food intake, and physical activity. METHODS: We performed an epidemiological triangulation combining cross-sectional, interventional, and Mendelian randomization study designs. In 5 independent clinical studies (n = 24-823), sOb-R was quantified in serum or plasma by commercial enzyme-linked immunosorbent assay kits using monoclonal antibodies. We performed mixed-model regression and 2-sample Mendelian randomization. RESULTS: In pooled, cross-sectional data, leveling by study, sOb-R was associated inversely with BMI (β [95% CI] −0.19 [−0.21 to −0.17]), body fat (−0.12 [−0.14 to −0.10), and fasting C-peptide (−2.04 [−2.46 to −1.62]). sOb-R decreased in response to acute hyperinsulinemia during euglycemic glucose clamp in 2 independent clinical studies (−0.5 [−0.7 to −0.4] and −0.5 [−0.6 to −0.3]), and immediately increased in response to intensive exercise (0.18 [0.04 to 0.31]) and food intake (0.20 [0.06 to 0.34]). In 2-sample Mendelian randomization, higher fasting insulin and higher BMI were causally linked to lower sOb-R levels (inverse variance weighted, −1.72 [−2.86 to −0.58], and −0.20 [−0.36 to −0.04], respectively). The relationship between hyperglycemia and sOb-R was inconsistent in cross-sectional studies and nonsignificant in intervention studies, and 2-sample Mendelian randomization suggested no causal effect of fasting glucose on sOb-R. CONCLUSION: BMI and insulin both causally decreased serum sOb-R levels. Conversely, intensive exercise and food intake acutely increased sOb-R. Our results suggest that sOb-R is involved in short-term regulation of leptin signaling, either directly or indirectly, and that hyperinsulinemia may reduce leptin signaling.
format Online
Article
Text
id pubmed-10099165
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-100991652023-04-14 Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans Sommer, Christine Vangberg, Kjersti G Moen, Gunn-Helen Evans, David M Lee-Ødegård, Sindre Blom-Høgestøl, Ingvild K Sletner, Line Jenum, Anne K Drevon, Christian A Gulseth, Hanne L Birkeland, Kåre I J Clin Endocrinol Metab Clinical Research Article CONTEXT: Serum soluble leptin receptor (sOb-R) may protect against future type 2 diabetes or serve as a marker for protective features, but how sOb-R is regulated is largely unknown. OBJECTIVE: This work aimed to test how serum sOb-R is influenced by glucose, insulin, body fat, body mass index (BMI), food intake, and physical activity. METHODS: We performed an epidemiological triangulation combining cross-sectional, interventional, and Mendelian randomization study designs. In 5 independent clinical studies (n = 24-823), sOb-R was quantified in serum or plasma by commercial enzyme-linked immunosorbent assay kits using monoclonal antibodies. We performed mixed-model regression and 2-sample Mendelian randomization. RESULTS: In pooled, cross-sectional data, leveling by study, sOb-R was associated inversely with BMI (β [95% CI] −0.19 [−0.21 to −0.17]), body fat (−0.12 [−0.14 to −0.10), and fasting C-peptide (−2.04 [−2.46 to −1.62]). sOb-R decreased in response to acute hyperinsulinemia during euglycemic glucose clamp in 2 independent clinical studies (−0.5 [−0.7 to −0.4] and −0.5 [−0.6 to −0.3]), and immediately increased in response to intensive exercise (0.18 [0.04 to 0.31]) and food intake (0.20 [0.06 to 0.34]). In 2-sample Mendelian randomization, higher fasting insulin and higher BMI were causally linked to lower sOb-R levels (inverse variance weighted, −1.72 [−2.86 to −0.58], and −0.20 [−0.36 to −0.04], respectively). The relationship between hyperglycemia and sOb-R was inconsistent in cross-sectional studies and nonsignificant in intervention studies, and 2-sample Mendelian randomization suggested no causal effect of fasting glucose on sOb-R. CONCLUSION: BMI and insulin both causally decreased serum sOb-R levels. Conversely, intensive exercise and food intake acutely increased sOb-R. Our results suggest that sOb-R is involved in short-term regulation of leptin signaling, either directly or indirectly, and that hyperinsulinemia may reduce leptin signaling. Oxford University Press 2022-12-02 /pmc/articles/PMC10099165/ /pubmed/36459457 http://dx.doi.org/10.1210/clinem/dgac699 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Research Article
Sommer, Christine
Vangberg, Kjersti G
Moen, Gunn-Helen
Evans, David M
Lee-Ødegård, Sindre
Blom-Høgestøl, Ingvild K
Sletner, Line
Jenum, Anne K
Drevon, Christian A
Gulseth, Hanne L
Birkeland, Kåre I
Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans
title Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans
title_full Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans
title_fullStr Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans
title_full_unstemmed Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans
title_short Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans
title_sort insulin and body mass index decrease serum soluble leptin receptor levels in humans
topic Clinical Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099165/
https://www.ncbi.nlm.nih.gov/pubmed/36459457
http://dx.doi.org/10.1210/clinem/dgac699
work_keys_str_mv AT sommerchristine insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans
AT vangbergkjerstig insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans
AT moengunnhelen insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans
AT evansdavidm insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans
AT leeødegardsindre insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans
AT blomhøgestølingvildk insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans
AT sletnerline insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans
AT jenumannek insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans
AT drevonchristiana insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans
AT gulsethhannel insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans
AT birkelandkarei insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans